JP2011526919A - イオンチャネルの阻害剤としての複素環式誘導体 - Google Patents
イオンチャネルの阻害剤としての複素環式誘導体 Download PDFInfo
- Publication number
- JP2011526919A JP2011526919A JP2011516842A JP2011516842A JP2011526919A JP 2011526919 A JP2011526919 A JP 2011526919A JP 2011516842 A JP2011516842 A JP 2011516842A JP 2011516842 A JP2011516842 A JP 2011516842A JP 2011526919 A JP2011526919 A JP 2011526919A
- Authority
- JP
- Japan
- Prior art keywords
- pain
- mmol
- acute
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*c1ccc(C(CC2)CN2C(CCN2c(cc3)cc(*)c3S(N(c3ncc[s]3)S(c3ccc(C)cc3)(=O)=O)(=O)=O)C2=O)cc1 Chemical compound C*c1ccc(C(CC2)CN2C(CCN2c(cc3)cc(*)c3S(N(c3ncc[s]3)S(c3ccc(C)cc3)(=O)=O)(=O)=O)C2=O)cc1 0.000 description 5
- NYDCEJULNFVTTC-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1c(cc1C)ccc1Cl)=O Chemical compound CC(C)(C)OC(N(CC1)CC1c(cc1C)ccc1Cl)=O NYDCEJULNFVTTC-UHFFFAOYSA-N 0.000 description 1
- REGWJCQNMMXFBM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1c1ccccc1)=O Chemical compound CC(C)(C)OC(N(CC1)CC1c1ccccc1)=O REGWJCQNMMXFBM-UHFFFAOYSA-N 0.000 description 1
- VJNWMCKMERHJDT-SANMLTNESA-N CC(C)(C)[Si+](c1ccccc1)(c1ccccc1)O[C@@H](CCO)C(Nc(cc1)ccc1S(Nc1ncc[s]1)(=O)=O)=O Chemical compound CC(C)(C)[Si+](c1ccccc1)(c1ccccc1)O[C@@H](CCO)C(Nc(cc1)ccc1S(Nc1ncc[s]1)(=O)=O)=O VJNWMCKMERHJDT-SANMLTNESA-N 0.000 description 1
- QYCDIKZHQNFLPA-SFHVURJKSA-N CC(C)(C)[Si+](c1ccccc1)(c1ccccc1)O[C@@H](CCO1)C1=O Chemical compound CC(C)(C)[Si+](c1ccccc1)(c1ccccc1)O[C@@H](CCO1)C1=O QYCDIKZHQNFLPA-SFHVURJKSA-N 0.000 description 1
- SCTXKBCMDPZWQG-LWOQYNTDSA-N CC(C)(O[C@@H]1CC(O)OC)OC1=O Chemical compound CC(C)(O[C@@H]1CC(O)OC)OC1=O SCTXKBCMDPZWQG-LWOQYNTDSA-N 0.000 description 1
- AXZMBXXTNXSOCI-RXMQYKEDSA-N CC(C)(O[C@@H]1CC=O)OC1=O Chemical compound CC(C)(O[C@@H]1CC=O)OC1=O AXZMBXXTNXSOCI-RXMQYKEDSA-N 0.000 description 1
- PRSIKIMSWSGWJX-IRSIHTCSSA-N CC([C@H]12)=C1C(N(CCC1O)C1=O)=CC=C2S(CCC(c1ncc[s]1)S(c1ccc(C)cc1)(=O)=O)(=O)=O Chemical compound CC([C@H]12)=C1C(N(CCC1O)C1=O)=CC=C2S(CCC(c1ncc[s]1)S(c1ccc(C)cc1)(=O)=O)(=O)=O PRSIKIMSWSGWJX-IRSIHTCSSA-N 0.000 description 1
- DGAVHFGEKNWVSY-SECBINFHSA-N CCCCCSC(C[C@H]1OC(C)(C)OC1=O)=O Chemical compound CCCCCSC(C[C@H]1OC(C)(C)OC1=O)=O DGAVHFGEKNWVSY-SECBINFHSA-N 0.000 description 1
- RGKKSBGKWUQYLH-ZCFIWIBFSA-N CCSC(C[C@H]1OC(C)(C)OC1=O)=O Chemical compound CCSC(C[C@H]1OC(C)(C)OC1=O)=O RGKKSBGKWUQYLH-ZCFIWIBFSA-N 0.000 description 1
- TVULPEBPCLTWOK-UHFFFAOYSA-N CNCc1ccc(C2CNCC2)cc1 Chemical compound CNCc1ccc(C2CNCC2)cc1 TVULPEBPCLTWOK-UHFFFAOYSA-N 0.000 description 1
- YRJNUBYQMLWRDT-SFHVURJKSA-N COc(cc1)ccc1S(N(c1ncc[s]1)S(c(cc1)ccc1N(CC[C@@H]1O)C1=O)(=O)=O)(=O)=O Chemical compound COc(cc1)ccc1S(N(c1ncc[s]1)S(c(cc1)ccc1N(CC[C@@H]1O)C1=O)(=O)=O)(=O)=O YRJNUBYQMLWRDT-SFHVURJKSA-N 0.000 description 1
- ZUTVMYPNLVKRCC-UHFFFAOYSA-N Cc1cc(C2CNCC2)ccc1Cl Chemical compound Cc1cc(C2CNCC2)ccc1Cl ZUTVMYPNLVKRCC-UHFFFAOYSA-N 0.000 description 1
- YGHCKDOMNUKAHH-ZDGMYTEDSA-N O=C(C(CC1)N(CC2)C[C@H]2c2cc(Cl)cc(Cl)c2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C(C(CC1)N(CC2)C[C@H]2c2cc(Cl)cc(Cl)c2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O YGHCKDOMNUKAHH-ZDGMYTEDSA-N 0.000 description 1
- ASMMKBAQPBVSFP-JTSKRJEESA-N O=C(Cc(cc1)ccc1N(CC[C@@H]1N(CC2)C[C@H]2c2cc(Cl)cc(Cl)c2)C1=O)Nc1ncc[s]1 Chemical compound O=C(Cc(cc1)ccc1N(CC[C@@H]1N(CC2)C[C@H]2c2cc(Cl)cc(Cl)c2)C1=O)Nc1ncc[s]1 ASMMKBAQPBVSFP-JTSKRJEESA-N 0.000 description 1
- USHOFMFWBAJTKM-WZONZLPQSA-N O=C([C@@H](CC1)N(CC2)C[C@@H]2c2cc(Cl)cc(Cl)c2)N1c1ccc(CCNc2ncc[s]2)cc1 Chemical compound O=C([C@@H](CC1)N(CC2)C[C@@H]2c2cc(Cl)cc(Cl)c2)N1c1ccc(CCNc2ncc[s]2)cc1 USHOFMFWBAJTKM-WZONZLPQSA-N 0.000 description 1
- YMRFWDLKXKZAPU-LFABVHOISA-N O=C([C@H](CC1)N(CC2)CC2c(cc2)ccc2Cl)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C([C@H](CC1)N(CC2)CC2c(cc2)ccc2Cl)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O YMRFWDLKXKZAPU-LFABVHOISA-N 0.000 description 1
- YGHCKDOMNUKAHH-FXMQYSIJSA-N O=C([C@H](CC1)N(CC2)CC2c2cc(Cl)cc(Cl)c2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C([C@H](CC1)N(CC2)CC2c2cc(Cl)cc(Cl)c2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O YGHCKDOMNUKAHH-FXMQYSIJSA-N 0.000 description 1
- QWRNZCGAJANSJL-UHFFFAOYSA-N OC(C(OC(C1)NCC1c1cc(Cl)cc(Cl)c1)=O)=O Chemical compound OC(C(OC(C1)NCC1c1cc(Cl)cc(Cl)c1)=O)=O QWRNZCGAJANSJL-UHFFFAOYSA-N 0.000 description 1
- ZTNJLBDJAZQLEQ-FANOUJGOSA-N O[C@@H](C(O)=O)c1cccc(C(C2)NC[C@H]2c2cc(Cl)cc(Cl)c2)c1 Chemical compound O[C@@H](C(O)=O)c1cccc(C(C2)NC[C@H]2c2cc(Cl)cc(Cl)c2)c1 ZTNJLBDJAZQLEQ-FANOUJGOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7722008P | 2008-07-01 | 2008-07-01 | |
| US61/077,220 | 2008-07-01 | ||
| PCT/US2009/049346 WO2010002956A2 (en) | 2008-07-01 | 2009-07-01 | Heterocyclic derivatives as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526919A true JP2011526919A (ja) | 2011-10-20 |
| JP2011526919A5 JP2011526919A5 (enExample) | 2012-08-09 |
Family
ID=41464851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516842A Pending JP2011526919A (ja) | 2008-07-01 | 2009-07-01 | イオンチャネルの阻害剤としての複素環式誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7846954B2 (enExample) |
| EP (1) | EP2307412A2 (enExample) |
| JP (1) | JP2011526919A (enExample) |
| KR (1) | KR20110025855A (enExample) |
| CN (1) | CN102099356A (enExample) |
| AU (1) | AU2009266979A1 (enExample) |
| CA (1) | CA2729681A1 (enExample) |
| IL (1) | IL210412A0 (enExample) |
| MX (1) | MX2010014193A (enExample) |
| RU (1) | RU2011103451A (enExample) |
| WO (1) | WO2010002956A2 (enExample) |
| ZA (1) | ZA201009128B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| CN101300253B (zh) * | 2005-09-09 | 2012-08-22 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道调控剂的二环衍生物 |
| AU2006306367A1 (en) * | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| CA2687764A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| WO2009064747A2 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
| RU2010123876A (ru) * | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| CA2714985C (en) | 2008-01-07 | 2018-05-15 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| WO2009133641A1 (ja) * | 2008-04-30 | 2009-11-05 | シャープ株式会社 | 照明装置、及び表示装置 |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| US8956346B2 (en) | 2010-05-14 | 2015-02-17 | Rainbow Medical, Ltd. | Reflectance-facilitated ultrasound treatment and monitoring |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104136442B (zh) * | 2012-01-16 | 2016-12-21 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 |
| US20170058302A1 (en) * | 2014-04-07 | 2017-03-02 | Praj Industries Limited | Method for efficient enzymatic hydrolysis of lignocellulosic materials |
| EP3484464B1 (en) | 2016-03-22 | 2020-10-28 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| HUE071358T2 (hu) | 2016-05-20 | 2025-08-28 | Xenon Pharmaceuticals Inc | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk |
| WO2017202376A1 (zh) * | 2016-05-26 | 2017-11-30 | 南京明德新药研发股份有限公司 | 磺酰胺衍生物 |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| JP7022751B2 (ja) | 2016-12-09 | 2022-02-18 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| SG11202011862PA (en) | 2018-06-13 | 2020-12-30 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN112638898B (zh) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| CN112759536A (zh) * | 2019-11-05 | 2021-05-07 | 常州锐博生物科技有限公司 | 取代的苯磺酰氯的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007075895A2 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2324013A (en) | 1941-07-31 | 1943-07-13 | Sharp & Dohme Inc | Amino-substituents of sulphanil-amide derivatives |
| NL130753C (enExample) | 1965-10-19 | |||
| US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| TW200524888A (en) | 2003-08-08 | 2005-08-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
| EP1737852A2 (en) * | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| RU2007145434A (ru) | 2005-05-10 | 2009-06-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов ионных каналов |
| US7745629B2 (en) | 2005-05-16 | 2010-06-29 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
| ZA200800191B (en) | 2005-06-09 | 2009-04-29 | Vertex Pharmaceuicals Inc | Indane derivatives as modulators of ion channels |
| CN101300253B (zh) | 2005-09-09 | 2012-08-22 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道调控剂的二环衍生物 |
| EP1934191B1 (en) * | 2005-10-12 | 2012-03-28 | Vertex Pharmaceuticals, Inc. | Biphenyl derivatives as modulators of voltage gated ion channels |
| AU2006306367A1 (en) | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| US7994174B2 (en) | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| RU2010123876A (ru) | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
-
2009
- 2009-07-01 EP EP09774406A patent/EP2307412A2/en not_active Withdrawn
- 2009-07-01 AU AU2009266979A patent/AU2009266979A1/en not_active Abandoned
- 2009-07-01 US US12/495,880 patent/US7846954B2/en active Active
- 2009-07-01 JP JP2011516842A patent/JP2011526919A/ja active Pending
- 2009-07-01 WO PCT/US2009/049346 patent/WO2010002956A2/en not_active Ceased
- 2009-07-01 CN CN200980127869XA patent/CN102099356A/zh active Pending
- 2009-07-01 CA CA2729681A patent/CA2729681A1/en not_active Abandoned
- 2009-07-01 RU RU2011103451/04A patent/RU2011103451A/ru not_active Application Discontinuation
- 2009-07-01 KR KR1020117002162A patent/KR20110025855A/ko not_active Withdrawn
- 2009-07-01 MX MX2010014193A patent/MX2010014193A/es not_active Application Discontinuation
-
2010
- 2010-10-28 US US12/913,869 patent/US8143297B2/en active Active
- 2010-12-20 ZA ZA2010/09128A patent/ZA201009128B/en unknown
- 2010-12-30 IL IL210412A patent/IL210412A0/en unknown
-
2012
- 2012-02-22 US US13/402,519 patent/US8343763B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007075895A2 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010014193A (es) | 2011-02-22 |
| CN102099356A (zh) | 2011-06-15 |
| ZA201009128B (en) | 2012-03-28 |
| IL210412A0 (en) | 2011-03-31 |
| US7846954B2 (en) | 2010-12-07 |
| CA2729681A1 (en) | 2010-01-07 |
| US20110098328A1 (en) | 2011-04-28 |
| EP2307412A2 (en) | 2011-04-13 |
| WO2010002956A3 (en) | 2010-06-10 |
| US8143297B2 (en) | 2012-03-27 |
| KR20110025855A (ko) | 2011-03-11 |
| US20120149742A1 (en) | 2012-06-14 |
| US8343763B2 (en) | 2013-01-01 |
| AU2009266979A1 (en) | 2010-01-07 |
| WO2010002956A2 (en) | 2010-01-07 |
| US20100004300A1 (en) | 2010-01-07 |
| RU2011103451A (ru) | 2012-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8143297B2 (en) | Heterocyclic derivatives as modulators of ion channels | |
| EP2231655B1 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain | |
| JP2010539244A (ja) | イオンチャネルのモジュレーターとしてのピリジルスルホンアミド | |
| JP2008540539A (ja) | イオンチャンネルの調節因子としての二環系誘導体 | |
| EP2220080B1 (en) | Heterocyclic derivatives as modulators of ion channels | |
| KR20080021030A (ko) | 이온 채널 조절인자로서의 바이사이클릭 유도체 | |
| KR20080019693A (ko) | 이온 채널 조절인자로서의 인단 유도체 | |
| KR20080059292A (ko) | 전압 개폐 이온 채널 조절인자로서의 바이페닐 유도체 | |
| HK1143582A (en) | Pyridyl sulfonamides as modulators of ion channels | |
| HK1146268A (en) | Heterocyclic derivatives as modulators of ion channels | |
| HK1119433B (en) | Indane derivatives as modulators of ion channels | |
| HK1119434A (en) | Bicyclic derivatives as modulators of ion channels | |
| HK1129096B (en) | Compositions useful as inhibitors of voltage-gated sodium channels | |
| HK1129096A1 (zh) | 適用作電壓-門控鈉通道抑制劑的組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120622 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120622 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140408 |